Comparing the effects of silver sulfadiazine and cerium nitrate silver sulfadiazine on burn-wound healing and survival rate of rat animal model

Yıl 2019, , 433 - 436, 28.06.2019

Latifi Nur-ahmad Fatemi-dokhtcharuk Mohammad-javad Salahi-kajur Ali-asghar Hedayatpour Azim

https://doi.org/10.28982/josam.515121

Cited By: 1

Öz

Aim: Current studies about burn therapy are focusing on survival rate of patients with severe burned. So, here we aim to assess the effects of cerium nitrate silver sulfadiazine (CN+SSD) and compare with SSD ointment on mortality and burn healing in rat animal model. 

Methods: Twenty rats were used in this study. After inducing burn wounds on back skin of animals, they were classified into two groups randomly. In one group, SSD was administrated topically immediately after inducing burn wound and in the other the combination of CN+SSD was applied. The treatments in both groups were continued as administration of the ointments two times per day for 28 days. Animal’s weight and wound sizes were measured 7, 14, 21 and 28 days after burn induction in all animals. The mortality of rats as well as their wound histopathology was also evaluated. 

Results: On day 28, wound’s average size was decreased to 25 and 27% of initial area in SSD and CN +SSD groups, respectively. In CN+SSD group, the wound size was not smaller than SSD group significantly. Histological comparison has demonstrated no significant differences between CN+SSD group and SSD treated. 

Conclusion: The results of our study did not show any differences between CN+SSD and SSD topical treatments in terms of wound healing and mortality rate in rat animal model significantly.

Anahtar Kelimeler

Skin-burn, Cerium nitrate silver sulfadiazine, Wound-healing, Mortality, Animal model

Gümüş sülfadiazin ve seryum nitrat gümüş sülfadiazin'in yanık yarası iyileşmesi ve sıçan hayvan modelinde sağkalım oranı üzerindeki etkilerinin karşılaştırılması

Öz

Amaç: Yanık tedavisi ile ilgili güncel çalışmalar, ciddi yanık hastalarının hayatta kalma oranlarına odaklanmaktadır. Bu nedenle, burada seryum nitrat gümüş sülfadiazin (CN+SSD) etkilerini değerlendirmeyi ve sıçan hayvan modelinde SSD merhem ile mortalite ve yanık iyileşmesi arasındaki karşılaştırmayı hedefledik.

Yöntemler: Bu çalışmada 20 rat kullanıldı. Hayvanların arka derisinde yanık yaraları indüklendikten sonra rastgele iki gruba ayrıldı. Bir grupta SSD, yanık yarasının indüklenmesinden hemen sonra topikal olarak uygulandı ve diğerinde CN+SSD'nin kombinasyonu uygulandı. Her iki grupta da, merhemlerin 28 gün boyunca günde iki kez uygulanmasına devam edildi. Animalin ağırlık ve yara ebatları, bütün hayvanlarda yanma indüksiyonundan 7, 14, 21 ve 28 gün sonra ölçüldü. Sıçanlardaki ölümlerin yanı sıra yara histopatolojileri de değerlendirildi.

Bulgular: 28. günde, yaranın ortalama büyüklüğü sırasıyla SSD ve CN+SSD gruplarında başlangıçtaki alanın %25 ve %27'sine düşürüldü. CN+SSD grubunda yara büyüklüğü SSD grubundan anlamlı derecede küçük değildi. Histolojik karşılaştırma, CN+SSD grubu ile tedavi edilen SSD arasında anlamlı bir fark olmadığını göstermiştir.

Sonuç: Çalışmamızın sonuçları, sıçan hayvan modelinde CN+SSD ve SSD topikal tedavileri arasında yara iyileşmesi ve mortalite oranı açısından anlamlı bir farklılık göstermedi.

Anahtar Kelimeler

Deri yanığı, Seryum nitrat gümüş sülfadiazin, Yara iyileşmesi, Mortalite, Hayvan modeli

Kaynakça

• 1. Daigeler A, Kapalschinski N, Lehnhardt M. [Therapy of burns]. Chir Z Für Alle Geb Oper Medizen. 2015 Apr;86(4):389–401.
• 2. Woods JFC, Quinlan CS, Shelley OP. Predicting Mortality in Severe Burns-What Is the Score?: Evaluation and Comparison of 4 Mortality Prediction Scores in an Irish Population. Plast Reconstr Surg Glob Open. 2016 Jan;4(1):e606.
• 3. Jugmohan B, Loveland J, Doedens L, Moore RL, Welthagen A, Westgarth-Taylor CJ. Mortality in paediatric burns victims: A retrospective review from 2009 to 2012 in a single centre. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 2016 Feb;106(2):189–92.
• 4. Arturson G. Forty years in burns research - the postburn inflammatory response. Burns J Int Soc Burn Inj. 2000 Nov;26(7):599–604.
• 5. Agee RN, Long JM, Hunt JL, Petroff PA, Lull RJ, Mason AD, et al. Use of 133xenon in early diagnosis of inhalation injury. J Trauma. 1976 Mar;16(3):218–24.
• 6. Barajas-Nava LA, López-Alcalde J, Roqué i Figuls M, Solà I, Bonfill Cosp X. Antibiotic prophylaxis for preventing burn wound infection. Cochrane Database Syst Rev. 2013;(6):CD008738.
• 7. Garner JP, Heppell PSJ. Cerium nitrate in the management of burns. Burns J Int Soc Burn Inj. 2005 Aug;31(5):539–47.
• 8. Nielson CB, Duethman N, Howard JM, Moncure M, Wood JG. Burns: Pathophysiology of Systemic Complications and Current Management. J Burn Care Res. 2017 Jan/Feb;38(1):e469-e481.
• 9. Oen IMMH, van Baar ME, Middelkoop E, Nieuwenhuis MK, Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plast Reconstr Surg. 2012 Aug;130(2):274e–283e.
• 10. De Gracia CG. An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns. Burns J Int Soc Burn Inj. 2001 Feb;27(1):67–74.
• 11. Fox CL, Monafo WW, Ayvazian VH, Skinner AM, Modak S, Stanford J, et al. Topical chemotherapy for burns using cerium salts and silver sulfadiazine. Surg Gynecol Obstet. 1977 May;144(5):668–72.
• 12. Monafo WW, Tandon SN, Ayvazian VH, Tuchschmidt J, Skinner AM, Deitz F. Cerium nitrate: a new topical antiseptic for extensive burns. Surgery. 1976 Oct;80(4):465–73.
• 13. Poredos P, Gradisek P, Testen C, Derganc M. Severe methemoglobinaemia due to benzocaine-containing “burn cream”: two case reports in an adult and in a child. Burns J Int Soc Burn Inj. 2011 Nov;37(7):e63–66.
• 14. Koo DS, Zhen S, Zhen ZD, Shi XW, Xiang SJ. Assessment of topical therapy of the burn wound with silver sulphadiazine after its use for 15 years in a burn unit. Burns J Int Soc Burn Inj. 1989 Jun;15(3):193–6.
• 15. Modak SM, Fox CL. Sulfadiazine silver-resistant Pseudomonas in Burns. New topical agents. Arch Surg Chic Ill 1960. 1981 Jul;116(7):854–7.
• 16. Bowser BH, Caldwell FT, Cone JB, Eisenach KD, Thompson CH. A prospective analysis of silver sulfadiazine with and without cerium nitrate as a topical agent in the treatment of severely burned children. J Trauma. 1981 Jul;21(7):558–63.
• 17. Munster AM, Helvig E, Rowland S. Cerium nitrate-silver sulfadiazine cream in the treatment of burns: a prospective evaluation. Surgery. 1980 Nov;88(5):658–60.
• 18. Jakupec MA, Unfried P, Keppler BK. Pharmacological properties of cerium compounds. Rev Physiol Biochem Pharmacol. 2005;153:101–11.
• 19. Monafo WW, Robinson HN. The treatment of burned children. Clin Plast Surg. 1977 Oct;4(4):537–46.
• 20. Fox CL, Modak SM, Stanford JW. Cerium sulphadiazine as a topical agent for burn wound infections: a comparison with silver sulphadiazine and zinc sulphadiazine. Burns. 1978;4(4):233–9.
• 21. Kistler D, Hafemann B, Schoenenberger GA, Hettich R. Increased survival rates by topical treatment of burns with cerium nitrate. Eur Surg Res Eur Chir Forsch Rech Chir Eur. 1990;22(5):283–90.
• 22. Hansbrough JF, Zapata-Sirvent R, Peterson V, Wang X, Bender E, Claman H, et al. Characterization of the immunosuppressive effect of burned tissue in an animal model. J Surg Res. 1984;37(5):383–93.
• 23. Peterson VM, Hansbrough JF, Wang XW, Zapata-Sirvent R, Boswick Jr JA. Topical cerium nitrate prevents postburn immunosuppression. J Trauma. 1985;25(11):1039–44.
• 24. Sparkes BG, Gyorkos JW, Gorczynski RM, Brock AJ. Comparison of endotoxins and cutaneous burn toxin as immunosuppressants. Burns. 1990;16(2):123–7.
• 25. Allgöwer M, Schoenenberger GA, Sparkes BG. Burning the largest immune organ. Burns. 1995;21:S7–S47.
• 26. Lorenz C, Specht U, Beyer W, Ströhmann F, Garbe S, Mau H. [Experiences with the use of cerium nitrate silver sulfadiazine in the local treatment of thermal injuries in childhood]. Zentralblatt Für Chir. 1988;113(19):1273–9.